Michael Schmidt
Stock Analyst at Guggenheim
(3.44)
# 957
Out of 4,555 analysts
54
Total ratings
50%
Success rate
4.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBTX Nanobiotix | Initiates: Buy | $12 | $5.12 | +134.38% | 1 | Aug 28, 2024 | |
| BOLT Bolt Biotherapeutics | Downgrades: Neutral | n/a | $0.63 | - | 2 | May 15, 2024 | |
| IMCR Immunocore Holdings | Reiterates: Buy | $92 | $33.87 | +171.63% | 2 | Apr 23, 2024 | |
| IMNM Immunome | Initiates: Buy | $35 | $14.62 | +139.40% | 1 | Apr 15, 2024 | |
| ADCT ADC Therapeutics | Reiterates: Buy | n/a | $2.75 | - | 2 | Apr 5, 2024 | |
| IMRX Immuneering | Downgrades: Neutral | n/a | $1.16 | - | 2 | Mar 14, 2024 | |
| MRSN Mersana Therapeutics | Upgrades: Buy | $7 | $1.50 | +366.67% | 2 | Feb 29, 2024 | |
| BGNE BeiGene | Maintains: Buy | $350 → $345 | $193.31 | +78.47% | 4 | Feb 27, 2024 | |
| ALLO Allogene Therapeutics | Downgrades: Neutral | n/a | $2.48 | - | 1 | Jan 5, 2024 | |
| INCY Incyte | Upgrades: Buy | n/a | $62.26 | - | 3 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $34 | $19.89 | +70.94% | 2 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $25.51 | +17.60% | 3 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $42 | $18.80 | +123.40% | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 | $1.48 | +1,251.35% | 3 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $82 | $86.55 | -5.26% | 1 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 | $9.79 | +53.22% | 3 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $25.12 | - | 1 | Jan 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $5 | $1.11 | +350.45% | 1 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $28 | $3.03 | +824.09% | 2 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $27.46 | - | 2 | Jan 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $3.07 | - | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $5.93 | +405.90% | 1 | Jul 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.26 | - | 1 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $42.12 | - | 1 | Mar 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.54 | - | 3 | Mar 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $43.93 | - | 3 | Feb 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.01 | - | 3 | Jan 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | n/a | $4.49 | - | 1 | Nov 7, 2017 |
Nanobiotix
Aug 28, 2024
Initiates: Buy
Price Target: $12
Current: $5.12
Upside: +134.38%
Bolt Biotherapeutics
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.63
Upside: -
Immunocore Holdings
Apr 23, 2024
Reiterates: Buy
Price Target: $92
Current: $33.87
Upside: +171.63%
Immunome
Apr 15, 2024
Initiates: Buy
Price Target: $35
Current: $14.62
Upside: +139.40%
ADC Therapeutics
Apr 5, 2024
Reiterates: Buy
Price Target: n/a
Current: $2.75
Upside: -
Immuneering
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.16
Upside: -
Mersana Therapeutics
Feb 29, 2024
Upgrades: Buy
Price Target: $7
Current: $1.50
Upside: +366.67%
BeiGene
Feb 27, 2024
Maintains: Buy
Price Target: $350 → $345
Current: $193.31
Upside: +78.47%
Allogene Therapeutics
Jan 5, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.48
Upside: -
Incyte
Dec 4, 2023
Upgrades: Buy
Price Target: n/a
Current: $62.26
Upside: -
Nov 8, 2023
Maintains: Buy
Price Target: $40 → $34
Current: $19.89
Upside: +70.94%
Oct 11, 2023
Reiterates: Buy
Price Target: $30
Current: $25.51
Upside: +17.60%
Jul 25, 2023
Maintains: Buy
Price Target: $40 → $42
Current: $18.80
Upside: +123.40%
Jun 27, 2023
Downgrades: Neutral
Price Target: $20
Current: $1.48
Upside: +1,251.35%
May 23, 2023
Maintains: Buy
Price Target: $78 → $82
Current: $86.55
Upside: -5.26%
Mar 21, 2023
Downgrades: Neutral
Price Target: $15
Current: $9.79
Upside: +53.22%
Jan 12, 2023
Downgrades: Neutral
Price Target: n/a
Current: $25.12
Upside: -
Jan 3, 2023
Upgrades: Buy
Price Target: $5
Current: $1.11
Upside: +350.45%
Nov 11, 2022
Maintains: Buy
Price Target: $55 → $28
Current: $3.03
Upside: +824.09%
Jan 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $27.46
Upside: -
Aug 10, 2021
Initiates: Buy
Price Target: n/a
Current: $3.07
Upside: -
Jul 19, 2021
Initiates: Buy
Price Target: $30
Current: $5.93
Upside: +405.90%
Apr 28, 2021
Downgrades: Neutral
Price Target: n/a
Current: $2.26
Upside: -
Mar 9, 2020
Initiates: Buy
Price Target: n/a
Current: $42.12
Upside: -
Mar 5, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $0.54
Upside: -
Feb 15, 2019
Upgrades: Outperform
Price Target: n/a
Current: $43.93
Upside: -
Jan 17, 2019
Initiates: Outperform
Price Target: n/a
Current: $6.01
Upside: -
Nov 7, 2017
Maintains: Market Perform
Price Target: n/a
Current: $4.49
Upside: -